LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
Titel:
LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
Auteur:
Neven, P. Fasching, P.A. Chia, S. Jerusalem, G. De Laurentiis, M. Im, S.-A. Petrakova, K. Bianchi, G.V. Martin Jimenez, M. Nusch, A. Sonke, G.S. de la Cruz Merino, L. Beck, J.T. Zarate, J.P. Wang, Y. Chakravartty, A. Wang, C. Slamon, D.